---
title: "TCT 2023: EVOLUT Low Risk trial shows continued strong performance for self-expanding TAVI platform out to four years"
date: "2023-10-24T18:58:35.000Z"
publishedDate: "24 octobre 2023"
summary: "At four years of follow-up, patients with severe aortic stenosis at low risk for surgery undergoing transcatheter aortic valve implantation (TAVI) with a self-expanding valve had a 26% reduction in hazard for death or disabling stroke compared to those undergoing surgical aortic valve replacement (SAVR). This was the latest finding from the Medtronic-funded EVOLUT Low [&#8230;] The post TCT 2023: EVOLUT Low Risk trial shows continued strong performance for self-expanding TAVI platform out to four years appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/evolut-low-risk-four-year-result/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2023-10-24-tct-2023-evolut-low-risk-trial-shows-continued-strong-performance-for-self-expanding-tavi-platform-out-to-four-years"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/10/IMG_7841.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/evolut-low-risk-four-year-result/"
---

![TCT 2023: EVOLUT Low Risk trial shows continued strong performance for self-expanding TAVI platform out to four years](https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/10/IMG_7841.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/evolut-low-risk-four-year-result/*

## L’essentiel

At four years of follow-up, patients with severe aortic stenosis at low risk for surgery undergoing transcatheter aortic valve implantation (TAVI) with a self-expanding valve had a 26% reduction in hazard for death or disabling stroke compared to those undergoing surgical aortic valve replacement (SAVR). This was the latest finding from the Medtronic-funded EVOLUT Low [&#8230;] The post TCT 2023: EVOLUT Low Risk trial shows continued strong performance for self-expanding TAVI platform out to four years appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/evolut-low-risk-four-year-result/
